Shares of ImmuPharma plc (LON:IMM – Get Free Report) dropped 11.6% on Wednesday . The company traded as low as GBX 2.50 ($0.03) and last traded at GBX 2.57 ($0.03). Approximately 6,519,809 shares were traded during trading, a decline of 43% from the average daily volume of 11,538,609 shares. The stock had previously closed at GBX 2.90 ($0.04).
ImmuPharma Trading Down 11.6 %
The company has a market cap of £10.90 million, a P/E ratio of -4.43 and a beta of 1.53. The business’s 50 day simple moving average is GBX 3.92 and its 200 day simple moving average is GBX 2.48.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- Should You Invest in Penny Stocks?
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- What is the S&P/TSX Index?
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Trading Stocks: RSI and Why it’s Useful
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
